Galapagos moves AbbVie-partnered drug into PhI as multipronged attack on CF takes shape

Nick Paul Taylor

has kicked off a Phase I trial of its AbbVie-partnered cystic fibrosis (CF) , GLPG2222. The start of the trial marks another milestone in the rolling advance of ' on CF, which is set to be bolstered later this year by the emergence of more next-generation correctors.

FierceBiotech News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS